Quarterly ResultApr 30, 2026, 07:22 AM
BAX Q1 Sales $2.7B, Adj. EPS $0.36; Declares $0.01 Dividend
AI Summary
Baxter International Inc. reported first-quarter 2026 sales from continuing operations of $2.7 billion, a 3% increase on a reported basis but a 1% decline organically. Adjusted diluted EPS from continuing operations was $0.36, a 35% decrease year-over-year, impacted by unfavorable comparisons and higher costs. The company reiterated its full-year 2026 financial outlook and declared a quarterly cash dividend of $0.01 per share. Strategic highlights included new product introductions and expansion of its continuous improvement system.
Key Highlights
- Declared a quarterly cash dividend of $0.01 per share, payable July 1, 2026.
- Q1 2026 sales from continuing operations were $2.7 billion, up 3% reported, down 1% organic.
- Adjusted diluted EPS from continuing operations was $0.03 (GAAP loss) and $0.36 (adjusted), a 35% decrease YoY.
- Medical Products & Therapies sales were $1.3 billion, up 2% reported, down 2% organic.
- Pharmaceuticals sales were $621 million, up 7% reported, up 1% organic.
- Reiterated full-year 2026 adjusted EPS guidance of $1.85 to $2.05.
- Free cash flow from continuing operations was $76 million, up from ($221) million YoY.